title: Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability.
abstract: Long-term nitroglycerin (NTG) treatment has been shown to be associated with cross-tolerance to endothelium-dependent vasodilators. It may involve increased production of reactive oxygen species (such as superoxide, O(2)(.-)) that rapidly inactivate the nitric oxide (NO) released from the endothelial cells. It remains to be elucidated, however, whether long-term treatment with NTG alters the activity and expression of the endothelial NO synthase (NOS III) and whether this enzyme can contribute to O(2)(.-) formation. We studied the influence of long-term NTG treatment on the expression of NOS III as assessed by RNase protection assay and Western blot. Tolerance was measured ex vivo in organ chamber experiments with rat aortic rings. O(2)(.-) and NO formation were quantified using lucigenin- and Cypridina luciferin analog-enhanced chemiluminescence as well as electron spin resonance (ESR) spectroscopy. Treatment of Wistar rats with NTG (Alzet osmotic minipumps, NTG concentration 10 microg x kg(-1) x min(-1)) for 3 days caused marked tolerance, cross-tolerance to the endothelium-dependent vasodilator acetylcholine, and a significant increase in O(2)(.-)-induced chemiluminescence. Tolerance was associated with a significant increase in NOS III mRNA to 236+/-28% and NOS III protein to 239+/-17%. In control vessels, the NOS inhibitor N(G)-nitro-L-arginine (L-NNA) increased the O(2)(.-)-mediated chemiluminescence, indicating that basal production of endothelium-derived NO depresses the baseline chemiluminescence signal. In the setting of tolerance, however, L-NNA decreased steady-state O(2)(.-) levels, indicating the involvement of NOS III in O(2)(.-) formation. Likewise, A23187-induced, NOS III-mediated O(2)(.-) production was more pronounced in tolerant than in control vessels. Vascular NO bioavailability as assessed with ESR spectroscopy using iron-thiocarbamate as a trap for NO was significantly reduced in tolerant vessels. Pretreatment of tolerant tissue in vitro with the protein kinase C (PKC) inhibitors reduced basal and stimulated NOS III-mediated O(2)(.-) production and partially reversed vascular tolerance. These findings suggest that NTG treatment increases the expression of a dysfunctional NOS III gene, leading to increased formation of O(2)(.-) and decreased vascular NO bioavailability. Normalization of NOS III-mediated O(2)(. -) production and improvement of tolerance with PKC inhibition suggests an important role for PKC isoforms in mediating vascular dysfunction caused by long-term NTG treatment.
authors.affiliation: University Hospital Eppendorf, Division of Cardiology, Hamburg, and the Department of Pharmacology, Johannes Gutenberg University, Mainz, Germany. muenzel@uke.uni-hamburg.de
authors.forename: T
authors.initials: T
authors.lastname: Münzel
authors.forename: H
authors.initials: H
authors.lastname: Li
authors.forename: H
authors.initials: H
authors.lastname: Mollnau
authors.forename: U
authors.initials: U
authors.lastname: Hink
authors.forename: E
authors.initials: E
authors.lastname: Matheis
authors.forename: M
authors.initials: M
authors.lastname: Hartmann
authors.forename: M
authors.initials: M
authors.lastname: Oelze
authors.forename: M
authors.initials: M
authors.lastname: Skatchkov
authors.forename: A
authors.initials: A
authors.lastname: Warnholtz
authors.forename: L
authors.initials: L
authors.lastname: Duncker
authors.forename: T
authors.initials: T
authors.lastname: Meinertz
authors.forename: U
authors.initials: U
authors.lastname: Förstermann
mesh_terms: D000109:Acetylcholine / Q000494:pharmacology; D000470:Alkaloids; D000818:Animals; D001120:Arginine / Q000494:pharmacology; D053119:Benzophenanthridines; D001682:Biological Availability; D000001:Calcimycin / Q000494:pharmacology; D002227:Carbazoles / Q000494:pharmacology; D003001:Cloning, Molecular; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D007211:Indoles / Q000494:pharmacology; D009569:Nitric Oxide / Q000378:metabolism*; D019001:Nitric Oxide Synthase / Q000096:biosynthesis / Q000235:genetics*; D052250:Nitric Oxide Synthase Type III; D005996:Nitroglycerin / Q000494:pharmacology*; D010617:Phenanthridines / Q000494:pharmacology; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000502:physiology; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D017208:Rats, Wistar; D013481:Superoxides / Q000378:metabolism*; D013995:Time; D014664:Vasodilation / Q000187:drug effects
chemical_list: D000470:Alkaloids; D053119:Benzophenanthridines; D002227:Carbazoles; D004791:Enzyme Inhibitors; D007211:Indoles; D010617:Phenanthridines; D012333:RNA, Messenger; D013481:Superoxides; C081021:Go 6976; D009569:Nitric Oxide; D000001:Calcimycin; D001120:Arginine; C016299:chelerythrine; D019001:Nitric Oxide Synthase; D052250:Nitric Oxide Synthase Type III; C496316:Nos3 protein, rat; D011493:Protein Kinase C; D005996:Nitroglycerin; D000109:Acetylcholine